The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York US FDA to convene expert panel to review wider access to some peptides Click the link in the comments below. When will the FDA reclassify BPC 157 to Category 1 Octagon AI Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law The internet says BPC 157 is banned the FDA says something more nuanced. At Moonshot Medical in Park Ridge, IL, we provide honest, current guidance on peptide therapy through licensed compounding pharmacies.